Interleukin-15-armored ALPPL2 CAR T cells demonstrate robust preclinical efficacy for solid tumors

Junquan Liu, Ningyan Zhang, Zhiqiang An, Andras Heczey

Open source

DOI
10.1016/j.omton.2026.201319
Published
2026-09
Container
Molecular Therapy Oncology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.omton.2026.201319,
  title = {Interleukin-15-armored ALPPL2 CAR T cells demonstrate robust preclinical efficacy for solid tumors},
  author = {Junquan Liu and Ningyan Zhang and Zhiqiang An and Andras Heczey},
  year = {2026},
  journal = {Molecular Therapy Oncology},
  doi = {10.1016/j.omton.2026.201319},
  url = {https://doi.org/10.1016/j.omton.2026.201319}
}

RIS

TY  - JOUR
TI  - Interleukin-15-armored ALPPL2 CAR T cells demonstrate robust preclinical efficacy for solid tumors
AU  - Junquan Liu
AU  - Ningyan Zhang
AU  - Zhiqiang An
AU  - Andras Heczey
PY  - 2026
JO  - Molecular Therapy Oncology
DO  - 10.1016/j.omton.2026.201319
UR  - https://doi.org/10.1016/j.omton.2026.201319
ER  - 

APA

Liu, J., Zhang, N., An, Z., & Heczey, A. (2026). Interleukin-15-armored ALPPL2 CAR T cells demonstrate robust preclinical efficacy for solid tumors. Molecular Therapy Oncology. https://doi.org/10.1016/j.omton.2026.201319

Source records